Product Description
Escient Pharmaceuticals is developing EP-547, an MRGPRX4-targeted oral therapy, as a treatment for cholestatic and uremic pruritus. (Sourced from: https://www.escientpharma.com/escient-pharmaceuticals-announces-positive-results-from-phase-1-study-of-ep547-an-mrgprx4-targeted-oral-therapy-for-cholestatic-and-uremic-pruritus/)
Mechanisms of Action: MRGPRX4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Escient Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Belgium, Canada, France, Israel, Netherlands, Spain, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Biliary Cirrhosis|Cholangitis, Sclerosing|Liver Cirrhosis|Pruritus